Coherus BioSciences CEO Departs, New Interim Officers Appointed
Ticker: CHRS · Form: 8-K · Filed: Apr 25, 2025 · CIK: 1512762
Sentiment: neutral
Topics: executive-change, management-transition
TL;DR
Coherus CEO Dennis Lanfear is OUT. New interim CMO & CSO named.
AI Summary
Coherus BioSciences, Inc. announced on April 22, 2025, changes in its executive team and board. Specifically, Dennis M. Lanfear has departed as Chief Executive Officer and from the Board of Directors. The company has also appointed Dr. Jose Luis Jimenez as interim Chief Medical Officer and Dr. Amit Agarwal as interim Chief Scientific Officer.
Why It Matters
Significant leadership changes at the CEO and executive level can impact a company's strategic direction and operational execution.
Risk Assessment
Risk Level: medium — CEO departure and appointment of interim officers can signal internal challenges or strategic shifts, increasing uncertainty.
Key Players & Entities
- Coherus BioSciences, Inc. (company) — Registrant
- Dennis M. Lanfear (person) — Departing CEO and Board Member
- Dr. Jose Luis Jimenez (person) — Appointed Interim Chief Medical Officer
- Dr. Amit Agarwal (person) — Appointed Interim Chief Scientific Officer
- April 22, 2025 (date) — Date of earliest event reported
FAQ
Who has been appointed as the interim Chief Medical Officer?
Dr. Jose Luis Jimenez has been appointed as the interim Chief Medical Officer.
Who has been appointed as the interim Chief Scientific Officer?
Dr. Amit Agarwal has been appointed as the interim Chief Scientific Officer.
What was Dennis M. Lanfear's role at Coherus BioSciences, Inc. before his departure?
Dennis M. Lanfear was the Chief Executive Officer and a member of the Board of Directors.
What is the exact date of the earliest event reported in this 8-K filing?
The earliest event reported is dated April 22, 2025.
What is the principal executive office address for Coherus BioSciences, Inc.?
The principal executive office is located at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA 94065.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 25, 2025 by Dennis M. Lanfear regarding Coherus BioSciences, Inc. (CHRS).